Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Complication of Transplant
Interventions
DRUG

Prograf

Administration of each formulation will be determined by sequence.

DRUG

Tacrolimus, Sandoz

Administration of each formulation will be determined by sequence.

DRUG

Tacrolimus, Reddy Laboratory

Administration of each formulation will be determined by sequence.

DRUG

Tacrolimus, Mylan

Administration of each formulation will be determined by sequence.

DRUG

Tacrolimus, Accord

Administration of each formulation will be determined by sequence.

DRUG

Tacrolimus, Pancea Biotech Limited

Administration of each formulation will be determined by sequence.

Trial Locations (1)

45267

University of Cincinnati Medical Center, Cincinnati

All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

lead

University of Cincinnati

OTHER

NCT02014103 - Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients | Biotech Hunter | Biotech Hunter